Advances in our molecular understanding of cancer mean we can selectively target specific patient profiles, leading to precision treatments in oncology. However, conducting clinical trials for sometimes rare subsets of patients can be logistically and technically challenging.
SPECTA (Screening Patients for Efficient Clinical Trial Access) is a collaborative European platform that helps deliver high-quality, translational research across tumour types and molecular alterations.
Through SPECTA, oncologists can allocate patients to clinical trials based on their clinical characteristics and the molecular profiles of their tumours. The platform provides a centralised mechanism, with rapid access to patient data and biological samples to enable the quick implementation of new clinical trials. And it provides access to state-of-the-art technical services for biobanking and molecular profiling, ensuring research is efficient, reproducible, traceable and high-quality.